Invesco
KRYS icon

Invesco’s Krystal Biotech KRYS Stock Holding History

Invesco’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$121M Buy
324,755
+73,382
+29% +$21.9M 0.01% 823
2026
Q1 		$64.9M Buy
251,373
+191,365
+319% +$50.9M 0.01% 982
2025
Q4 		$14.8M Sell
60,008
-6,872
-10% -$1.45M ﹤0.01% 1621
2025
Q3 		$11.8M Sell
66,880
-4,008
-6% -$600K ﹤0.01% 1728
2025
Q2 		$9.74M Sell
70,888
-183,598
-72% -$27M ﹤0.01% 1787
2025
Q1 		$45.9M Sell
254,486
-20,709
-8% -$3.48M 0.01% 1071
2024
Q4 		$43.1M Sell
275,195
-90,356
-25% -$16M 0.01% 1115
2024
Q3 		$66.5M Buy
365,551
+90,474
+33% +$17.4M 0.01% 931
2024
Q2 		$50.5M Buy
275,077
+185,449
+207% +$31.1M 0.01% 1006
2024
Q1 		$15.9M Buy
89,628
+35,399
+65% +$4.92M ﹤0.01% 1560
2023
Q4 		$6.73M Buy
54,229
+10,030
+23% +$1.11M ﹤0.01% 2072
2023
Q3 		$5.13M Sell
44,199
-21,009
-32% -$2.56M ﹤0.01% 2198
2023
Q2 		$7.66M Buy
65,208
+13,628
+26% +$1.39M ﹤0.01% 1992
2023
Q1 		$4.13M Buy
51,580
+23,537
+84% +$1.85M ﹤0.01% 2314
2022
Q4 		$2.22M Sell
28,043
-23,565
-46% -$1.75M ﹤0.01% 2603
2022
Q3 		$3.6M Buy
51,608
+42,454
+464% +$3.07M ﹤0.01% 2381
2022
Q2 		$600K Buy
9,154
+1,404
+18% +$87.3K ﹤0.01% 3243
2022
Q1 		$515K Buy
7,750
+69
+0.9% +$4.31K ﹤0.01% 3374
2021
Q4 		$538K Sell
7,681
-455
-6% -$26.5K ﹤0.01% 3358
2021
Q3 		$425K Buy
8,136
+931
+13% +$55.1K ﹤0.01% 3503
2021
Q2 		$489K Buy
7,205
+3,454
+92% +$241K ﹤0.01% 3432
2021
Q1 		$289K Buy
+3,751
New +$273K ﹤0.01% 3566
2020
Q2 		– Sell
-34,701
Closed -$1.5M – 3667
2020
Q1 		$1.5M Sell
34,701
-47,632
-58% -$2.49M ﹤0.01% 2553
2019
Q4 		$4.56M Buy
82,333
+35,123
+74% +$1.72M ﹤0.01% 2218
2019
Q3 		$1.64M Buy
+47,210
New +$2.11M ﹤0.01% 2736
2019
Q1 		– Sell
-47,113
Closed -$979K – 3762
2018
Q4 		$979K Buy
+47,113
New +$986K ﹤0.01% 2991

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Invesco's KRYS Position: Q2 2026 in Review

Invesco increased its Krystal Biotech (KRYS) stake by 29% in Q2 2026, buying an estimated $21.9M and bringing the position to 324,755 shares worth $121M. The position accounts for 0.01% of the portfolio, ranked #823.

Invesco first reported a position in KRYS in Q4 2018 and has held it in 26 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Invesco held 324,755 shares of Krystal Biotech worth $121M as of Q2 2026.
  • Invesco bought 73,382 Krystal Biotech shares in Q2 2026, an estimated $21.9M.
  • Krystal Biotech made up 0.01% of Invesco's portfolio in Q2 2026, its #823 holding.
  • Invesco first reported a position in Krystal Biotech in Q4 2018 and has held it in 26 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.